Antitumor Activity of HM781-36B, Alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose HM781-36B is a novel and irreversible pan-human epidermal growth factor receptor (HER) inhibitor with TEC cytoplasmic kinase inhibition. The aim of this study is to evaluate the antitumor activity and mechanism of action for HM781-36B in colorectal cancer (CRC) cell lines. Materials and Methods The CRC cell lines were exposed to HM781-36B and/or oxaliplatin (L-OHP), 5-fluorouracil (5-FU), SN-38. The cell viability was examined by Cell Titer-Glo luminescent cell viability assay kit. Change in the cell cycle and protein expression was determined by flow cytometry and immunoblot analysis, respectively. Synergism between two drugs was evaluated by the com- bination index. Results The addition of HM781-36B induced potent growth inhibition in both DiFi cells with epider- mal growth factor receptor (EGFR) overexpression and SNU-175 cells (IC50, 0.003 µM and 0.005 µM, respectively). Furthermore, HM781-36B induced G1 arrest of the cell cycle and apoptosis, and reduced the levels of HER family and downstream signaling molecules, pERK and pAKT, as well as nonreceptor/cytoplasmic tyrosine kinase, BMX. The combination of HM781-36B with 5-FU, L-OHP, or SN-38 showed an additive or synergistic effect in most CRC cells. Conclusion These findings suggest the potential roles of HM781-36B as the treatment for EGFR-over- expressing colon cancer, singly or in combination with chemotherapeutic agents. The role of BMX expression as a marker of response to HM781-36B should be further explored.
Abstract
Purpose HM781-36B is a novel and irreversible pan-human epidermal growth factor receptor (HER) inhibitor with TEC cytoplasmic kinase inhibition. The aim of this study is to evaluate the antitumor activity and mechanism of action for HM781-36B in colorectal cancer (CRC) cell lines. Materials and Methods The CRC cell lines were exposed to HM781-36B and/or oxaliplatin (L-OHP), 5-fluorouracil (5-FU), SN-38. The cell viability was examined by Cell Titer-Glo luminescent cell viability assay kit. Change in the cell cycle and protein expression was determined by flow cytometry and immunoblot analysis, respectively. Synergism between two drugs was evaluated by the com- bination index. Results The addition of HM781-36B induced potent growth inhibition in both DiFi cells with epider- mal growth factor receptor (EGFR) overexpression and SNU-175 cells (IC50, 0.003 µM and 0.005 µM, respectively). Furthermore, HM781-36B induced G1 arrest of the cell cycle and apoptosis, and reduced the levels of HER family and downstream signaling molecules, pERK and pAKT, as well as nonreceptor/cytoplasmic tyrosine kinase, BMX. The combination of HM781-36B with 5-FU, L-OHP, or SN-38 showed an additive or synergistic effect in most CRC cells. Conclusion These findings suggest the potential roles of HM781-36B as the treatment for EGFR-over- expressing colon cancer, singly or in combination with chemotherapeutic agents. The role of BMX expression as a marker of response to HM781-36B should be further explored.
참고문헌 (25)
- Venook A, "Critical evaluation of current treatments in metastatic colorectal cancer", Oncologist, 10, pp.250~261 (2005)
- McKay JA, "Evaluation of the epidermal growth factor receptor(EGFR)in colorectal tumours and lymph node metastases", Eur J Cancer, 38, pp.2258~2264 (2002)
- Hynes NE, "ERBB receptors and cancer : the complexity of targeted inhibitors", Nat Rev Cancer, 5, pp.341~354 (2005)
- Wong SF, "Cetuximab : an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer", Clin Ther, 27, pp.684~694 (2005)
- Kobayashi S, "EGFR mutation and resistance of nonsmall-cell lung cancer to gefitinib", N Engl J Med, 352, pp.786~792 (2005)
- Dienstmann R, "Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer", Mol Oncol, 6, pp.15~26 (2012)
- Cameron D, "Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer : final survival analysis of a phase III randomized trial", Oncologist, 15, pp.924~934 (2010)
- Carter TA, "Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases", Proc Natl Acad Sci U S A, 102, pp.11011~11016 (2005)
- Marrero-Ponce Y, "Prediction of tyrosinase inhibition activity using atom-based bilinear indices", ChemMedChem, 2, pp.449~478 (2007)
- Nam HJ, "Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer", Cancer Lett, 302, pp.155~165 (2011)
- Cha MY, "Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models", Int J Cancer, 130, pp.2445~2454 (2012)
- Ahmed D, "Epigenetic and genetic features of 24 colon cancer cell lines", Oncogenesis, 2, pp.71~ (2013)
- Lee J, "Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations", J Natl Cancer Inst, 103, pp.674~688 (2011)
- Janakiraman M, "Genomic and biological characterization of exon 4 KRAS mutations in human cancer", Cancer Res, 70, pp.5901~5911 (2010)
- Achmad A, "Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Culabeled cetuximab positron emission tomography", Cancer Sci, 103, pp.600~605 (2012)
- Chou TC, "Quantitative analysis of dose-effect relationships : the combined effects of multiple drugs or enzyme inhibitors", Adv Enzyme Regul, 22, pp.27~55 (1984)
- Rothenberg ML, "Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma", J Clin Oncol, 23, pp.9265~9274 (2005)
- Fisher GA, "A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer", Clin Cancer Res, 14, pp.7074~7079 (2008)
- Kuo T, "Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer", Clin Colorectal Cancer, 5(Suppl 2), pp.62~70 (2005)
- Lenz HJ, "Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines", J Clin Oncol, 24, pp.4914~4921 (2006)
- Modjtahedi H, "Epidermal growth factor receptor inhibitors in cancer treatment : advances, challenges and opportunities", Anticancer Drugs, 20, pp.851~855 (2009)
- Ciardiello F, "EGFR antagonists in cancer treatment", N Engl J Med, 358, pp.1160~1174 (2008)
- Hur W, "Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase", Bioorg Med Chem Lett, 18, pp.5916~5919 (2008)
- Kim HJ, "Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells", Anticancer Drugs, 23, pp.288~297 (2012)
- Jarboe JS, "Mini-review : bmx kinase inhibitors for cancer therapy", Recent Pat Anticancer Drug Discov, 8, pp.228~238 (2013)